Dianthus Therapeutics, Inc. Common Stock
Symbol: DNTH (NASDAQ)
35.82
▼ (-0.50%) -0.180
Company Description:
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Key Stats
- Today's Open: $35.99
- Today's High: $36.599
- Today's Low: $35.415
- Today's Volume: 34.46K
- Yesterday Close: $36
- Yesterday High: $37.5
- Yesterday Low: $35.3
- Yesterday Volume: 447.78K
- Last Min Volume: 162
- Last Min High: $35.875
- Last Min Low: $35.862
- Last Min VWAP: $35.87441
Company Profile
- Name: Dianthus Therapeutics, Inc. Common Stock
- Website: https://www.dianthustx.com
- Listed Date: 2023-09-12
- Location: NEW YORK, NY
- Market Status: Active
- CIK Number: 0001690585
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.43B
- Round Lot: 100
- Outstanding Shares: 39.82M
- Asset Type: CS
RECENT FILINGS FOR DNTH
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-16 | 8-K | View |
| 2025-10-03 | 4 | View |
| 2025-09-25 | 4 | View |
| 2025-09-25 | 4 | View |
| 2025-09-15 | SCHEDULE 13D/A | View |
| 2025-09-12 | SCHEDULE 13G | View |
| 2025-09-11 | 4 | View |
| 2025-09-11 | 8-K | View |
| 2025-09-11 | 424B5 | View |
| 2025-09-09 | 144 | View |
| 2025-09-08 | 424B5 | View |
| 2025-09-08 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-05-22 | 4 | View |
| 2025-05-22 | 4 | View |
Latest News on DNTH